A specific molecular marker may help predict whether patients with a common subtype of acute myeloid leukemia (AML) will experience a relapse after treatment. This could lead to more aggressive treatment with stem cell transplantation or incorporation of tyrosine kinase inhibitors targeting the specific gene.
Go to Previous Page
Go to Next Page